Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma
- 31 August 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 114 (2) , 265-269
- https://doi.org/10.1016/j.jaci.2004.05.049
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Unmet Needs in the Treatment of Allergic Asthma: Potential Role of Novel Biologic TherapiesJournal of Managed Care Pharmacy, 2003
- Omalizumab improves asthma-related quality of life in patients with severe allergic asthmaJournal of Allergy and Clinical Immunology, 2003
- Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthmaJournal of Allergy and Clinical Immunology, 2003
- The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthmaEuropean Respiratory Journal, 2002
- Inhaled corticosteroid dose-reducing effect of omalizumab in patients with controlled, severe asthma according to usage of inhaled long-acting beta-agonistsJournal of Allergy and Clinical Immunology, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)Pediatrics, 2001
- The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsEuropean Respiratory Journal, 2001
- The health economics of asthma and rhinitis. I. Assessing the economic impactJournal of Allergy and Clinical Immunology, 2001
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999